PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-16.26%
Negative revenue growth while MCHP stands at 2.98%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-26.53%
Negative gross profit growth while MCHP is at 3.13%. Joel Greenblatt would examine cost competitiveness or demand decline.
22.34%
Positive EBIT growth while MCHP is negative. John Neff might see a substantial edge in operational management.
-80.00%
Negative operating income growth while MCHP is at 6.00%. Joel Greenblatt would press for urgent turnaround measures.
-84.11%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-88.89%
Negative EPS growth while MCHP is at 5.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-88.89%
Negative diluted EPS growth while MCHP is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.47%
Share reduction while MCHP is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.62%
Reduced diluted shares while MCHP is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
0.47%
Dividend growth under 50% of MCHP's 1.01%. Michael Burry might suspect more pressing needs for cash or weaker earnings power.
-77.55%
Negative OCF growth while MCHP is at 41.21%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-80.02%
Negative FCF growth while MCHP is at 52.63%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
28.28%
10Y revenue/share CAGR under 50% of MCHP's 147.96%. Michael Burry would suspect a lasting competitive disadvantage.
-3.43%
Negative 5Y CAGR while MCHP stands at 77.46%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-22.22%
Negative 3Y CAGR while MCHP stands at 33.86%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
45.03%
10Y OCF/share CAGR under 50% of MCHP's 369.09%. Michael Burry would worry about a persistent underperformance in cash creation.
-13.19%
Negative 5Y OCF/share CAGR while MCHP is at 93.75%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.98%
Negative 3Y OCF/share CAGR while MCHP stands at 42.84%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-91.64%
Negative 10Y net income/share CAGR while MCHP is at 449.53%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-93.70%
Negative 5Y net income/share CAGR while MCHP is 504.63%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-96.39%
Negative 3Y CAGR while MCHP is 36.40%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
72.90%
Below 50% of MCHP's 197.01%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
3.59%
Positive 5Y equity/share CAGR while MCHP is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
1.88%
Positive short-term equity growth while MCHP is negative. John Neff sees a strong advantage in near-term net worth buildup.
435.74%
Dividend/share CAGR of 435.74% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
417.97%
Below 50% of MCHP's 1230.06%. Michael Burry worries the firm returns far less capital to shareholders over 5 years.
265.17%
3Y dividend/share CAGR 1.25-1.5x MCHP's 236.01%. Bruce Berkowitz checks if the company's short-term profits or payout policy justify these higher hikes.
23.22%
Our AR growth while MCHP is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-20.15%
Inventory is declining while MCHP stands at 1.06%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-3.38%
Negative asset growth while MCHP invests at 1.24%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.78%
We have a declining book value while MCHP shows 1.57%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-10.44%
Our R&D shrinks while MCHP invests at 0.15%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-15.75%
We cut SG&A while MCHP invests at 0.04%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.